LNWTC
CRDL

Laird Norton Wetherby Trust Company’s Cardiol Therapeutics CRDL Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$202K – 87
2024
Q2 		$202K Hold
100,000
– – 0.03% 57
2024
Q1 		$181K Hold
100,000
– – 0.02% 66
2023
Q4 		$84.3K Hold
100,000
– – 0.01% 79
2023
Q3 		$89.5K Buy
100,000
+38,673
+63% +$36.9K 0.01% 112
2023
Q2 		$54.6K Hold
61,327
– – 0.01% 113
2023
Q1 		$29.9K Buy
+61,327
New +$36.3K ﹤0.01% 118

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Laird Norton Wetherby Trust Company's CRDL Position: Q3 2024 in Review

Laird Norton Wetherby Trust Company sold out of Cardiol Therapeutics (CRDL) in Q3 2024, closing a stake of 100,000 shares — an estimated $202K sold.

Laird Norton Wetherby Trust Company first reported a position in CRDL in Q1 2023 and held it in 6 quarters. The position peaked at $202K in Q2 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q3 2024.

  • Laird Norton Wetherby Trust Company reported no remaining Cardiol Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Laird Norton Wetherby Trust Company sold 100,000 Cardiol Therapeutics shares in Q3 2024, an estimated $202K.
  • Laird Norton Wetherby Trust Company first reported a position in Cardiol Therapeutics in Q1 2023 and held it in 6 quarters.
  • Laird Norton Wetherby Trust Company's Cardiol Therapeutics position peaked at $202K in Q2 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2024.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q3 2024, filed 14 Nov 2024.